What retatrutide is
Published chemistry, not a measurement from any lot.
Retatrutide, development code LY3437943, is a synthetic lipidated peptide built on a glucagon-family backbone, with non-standard residues and a fatty-diacid side chain attached to a lysine. The FDA's substance registry records a 39-residue backbone, YAQGTFTSDYSILLDKKAQAAFIEYLLEGGPSSGAPPPS, under UNII NOP2Y096GV, and the primary paper describes the Aib substitutions and the C20 diacid conjugate that are not visible in the plain letter sequence.
Two naming points matter before anything else. GP-3 is a Marogen catalog label, not a chemical name, and the pen is listed as GLP-3, which is worse: there is no natural hormone called GLP-3. Retatrutide is the only name that identifies the molecule. The second point is that the formula and weight below could not be confirmed in CAS Common Chemistry or the FDA registry; they match PubChem and vendor datasheets, which is why Marogen marks the entry as awaiting confirmation.
- CAS
- 2381089-83-2 · awaiting confirmation
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.3 g/mol
- Sequence
- 39-residue GIP/GLP-1/glucagon triple agonist
- Residues
- 39
- Also searched as
- reta, GP-3, LY3437943
Compiled from public chemistry records (PubChem, FDA GSRS, UniProt). Values marked “awaiting confirmation” are not yet confirmed by Marogen. The certificate for a lot is the authority for every number on it. See the analytical reference table.
Formats Marogen stocks
Every retatrutide listing in the catalog, with sizes and SKUs.
The lyophilized vial has the widest size range in the catalog, six strengths from 5 mg to 60 mg, which signals that this material is bought by labs working at very different scales. It is the format for analytical work, because the solid can be weighed and made up to a known concentration.
The second format is a 20 mg prefilled research pen, listed under the name GLP-3. The pen's concentration and fill volume are not published, because they are supplier product facts Marogen has not put on the site, and only the total content appears. If concentration matters to your method, buy the vial or have the figure stated on the quote. There is no retatrutide nasal spray.
| Listing | Form | Sizes | SKU | Documentation |
|---|---|---|---|---|
| Retatrutide (GP-3) Reference Standard | Lyophilized powder, sealed vial | 5 mg10 mg15 mg20 mg30 mg60 mg | GP3-5MGGP3-10MGGP3-15MGGP3-20MGGP3-30MGGP3-60MG | Lot RETA10-1008 on file |
| GLP-3 | Prefilled research pen | 20 mg | PEN-GLP3-20 | Not yet published |
2 catalog listings are covered here. Sizes, SKUs and documentation status are read from the catalog at build time. Blends contain more than one molecule, so only single-component listings behave as a single-analyte standard. Pricing is per account: see wholesale pricing.
What a certificate of analysis must show
At 4,731 g/mol, the certificate has to work harder.
A 39-residue lipidated peptide is not a material one purity number can cover. Identity has to come from several charge states, because the singly charged ion is not useful at this mass: the quadruply charged ion sits near m/z 1183.8 and the quintuply charged near 947.3. Purity by reverse-phase HPLC is still the right method, but the related substances are deletion sequences and incompletely acylated material rather than oxidation products.
The side chain is the field most often missing. A peptide with the correct backbone but no fatty-diacid conjugate is a different compound, several hundred daltons lighter, and one of the likelier manufacturing failures. A certificate should state that the acylation is present and quantify unacylated material. Marogen publishes certificates by lot number at marogenbio.com/coa, with a lookup at marogenbio.com/lot. No retatrutide lot has one today.
| Field | What it has to say for retatrutide |
|---|---|
| Material name | Retatrutide or LY3437943. A certificate that says only GP-3 or GLP-3 does not identify a molecule |
| Lot number | As printed on the vial or pen, matching the label exactly |
| Identity | Observed against calculated mass across charge states: near m/z 1183.8 for [M+4H]4+ and 947.3 for [M+5H]5+, from 4731.3 g/mol |
| Mass basis | Which formula and weight the laboratory used, since no public database carries an authoritative figure |
| Side chain | That the fatty-diacid conjugate is present, with unacylated material quantified separately |
| Purity | Area percent by reverse-phase HPLC with gradient and wavelength stated |
| Related substances | Deletion sequences and incompletely acylated peptide, named rather than pooled |
| Salt form | Free peptide, sodium salt or acetate. Each gives a different weighing basis |
| Content | Milligrams actually present, reported separately from purity |
Storage and handling in the lab
Large lipidated peptides bring a problem short peptides do not have: physical instability as well as chemical. The fatty-diacid chain makes the molecule surface-active, so it can adsorb to glass and plastic and can aggregate in solution, and both cost you concentration without changing purity. Marogen does not publish per-material storage conditions, so confirm the condition for your lot with the wholesale team. The points below are general laboratory practice, not a Marogen specification.
- Keep the lyophilized solid sealed, dry and cold, and bring the vial to room temperature before opening so moisture does not condense into the powder.
- Expect adsorption losses on surfaces when working at low concentration, and keep handling steps and transfers to a minimum.
- Avoid shaking and repeated freezing and thawing of made-up solutions. Aggregation in a lipidated peptide is a physical change a purity figure will not show.
- Record the lot number, the salt form and the mass basis together, since the last two determine what a concentration figure actually means.
Telling it apart from related compounds
Retatrutide sits beside tirzepatide and semaglutide in most catalogs, and all three are large lipidated incretin-family analogues with broadly similar chromatography. Mass separates them, but only if the certificate reports it properly: the gap between retatrutide at 4731.3 and tirzepatide at 4813.5 is about 82 Da, under two percent.
| Material | How it differs and how to check |
|---|---|
| Tirzepatide (GP-2) | 4813.5 g/mol against 4731.3, roughly 82 Da apart, and a different backbone. Marogen lists it separately as a reference standard and a pen |
| Semaglutide (GP-1) | A smaller GLP-1 analogue near 4113 g/mol with a different side chain. Clearly separable by mass |
| Backbone without the side chain | Several hundred daltons lighter and much more polar, so retention shifts noticeably. A manufacturing failure, not a grade |
| GLP-2, the real hormone | A distinct natural 33-residue intestinal hormone. The pen name GLP-3 is invented; GLP-2 belongs to something else entirely |
What the published literature measured
The primary record for this molecule is small and recent, which is worth knowing when a datasheet cites structural detail. Two papers carry nearly all of it: the discovery and in-vitro pharmacology paper, and the first-in-human pharmacokinetic study.
Coskun T, Urva S, Roell WC, et al.. Cell Metabolism 2022; 34:1234-1247.
Reported the molecule's design and measured in-vitro potency at the glucagon, GIP and GLP-1 receptors, the primary source for its structure.
Urva S, Coskun T, Loh MT, et al.. The Lancet 2022; 400:1869-1881.
Reported plasma concentration-time profiles and an apparent half-life of roughly six days for the compound in a phase 1b study.
Wholesale availability
The retatrutide vial in six sizes and the 20 mg pen are supplied wholesale, priced per account rather than from a public list. Because the public chemistry is incomplete, ask in the pricing request what the lot's certificate states for formula, mass basis and salt form.
Apply for wholesale pricing
List the materials, sizes and units you need, or ask about the range, and say a little about the business. Pricing is set per account and confirmed on every quote, with the lot’s documentation status stated for each line.
Questions
Is GP-3 or GLP-3 the name of a real molecule?
No. GP-3 is a Marogen catalog label and GLP-3 is the name on the pen, and neither is a chemical name. There is no natural hormone called GLP-3. The molecule is retatrutide, development code LY3437943, and that is the name to use in a specification, purchase order or method document. A certificate identifying the material only as GP-3 or GLP-3 has not identified a molecule.
What is retatrutide as a molecule?
A synthetic lipidated peptide on a glucagon-family backbone. The FDA substance registry records a 39-residue backbone under UNII NOP2Y096GV, and the primary paper describes Aib substitutions and a C20 fatty-diacid side chain on a lysine. The published formula C221H342N46O68 and weight of 4731.3 g/mol match PubChem and vendor datasheets but are not confirmed in CAS Common Chemistry or the registry.
What formats does Marogen stock retatrutide in?
Two: a lyophilized vial in six strengths from 5 mg to 60 mg, the widest size range in the catalog, and a 20 mg prefilled research pen listed as GLP-3. There is no nasal spray. The pen's concentration and fill volume are not published, only its total content.
What should a retatrutide certificate of analysis show?
The molecule named as retatrutide, the lot number, the testing laboratory and date, identity reported across several charge states rather than one, the formula and mass basis the laboratory used, evidence that the fatty-diacid side chain is present with unacylated material quantified, purity by reverse-phase HPLC with the method stated, the salt form, and content in milligrams separate from purity.
How is retatrutide different from tirzepatide?
They are different molecules with different backbones, about 82 Da apart: 4731.3 g/mol for retatrutide against 4813.5 for tirzepatide. Both are large lipidated incretin-family analogues with broadly similar chromatography, so a certificate needs a properly reported mass across charge states to separate them with confidence. Marogen lists them as separate reference standards and separate pens.
Research use only. This guide describes materials supplied for in-vitro research and analytical method development. Nothing here is dosing, administration or use information, and no product on this site is offered for human or animal consumption. See the research use policy.